Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics

Concert Pharmaceuticals, Inc. (CNCE): $4.42

-0.10 (-2.21%)

POWR Rating

Component Grades













Add CNCE to Watchlist
Sign Up

Industry: Biotech



in industry


  • CNCE scores best on the Growth dimension, with a Growth rank ahead of 74.23% of US stocks.
  • The strongest trend for CNCE is in Growth, which has been heading up over the past 177 days.
  • CNCE's current lowest rank is in the Stability metric (where it is better than 14.33% of US stocks).

CNCE Stock Summary

  • Of note is the ratio of CONCERT PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 6.64% of US stocks have a lower such ratio.
  • CNCE's price/sales ratio is 5,432.99; that's higher than the P/S ratio of 99.89% of US stocks.
  • Revenue growth over the past 12 months for CONCERT PHARMACEUTICALS INC comes in at -99.87%, a number that bests merely 0.59% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to CONCERT PHARMACEUTICALS INC, a group of peers worth examining would be KZIA, AUTL, HGEN, MGNX, and ABUS.
  • Visit CNCE's SEC page to see the company's official filings. To visit the company's web site, go to

CNCE Valuation Summary

  • CNCE's price/earnings ratio is -1.8; this is 107.69% lower than that of the median Healthcare stock.
  • CNCE's EV/EBIT ratio has moved up 50.6 over the prior 107 months.

Below are key valuation metrics over time for CNCE.

Stock Date P/S P/B P/E EV/EBIT
CNCE 2022-12-02 5547.6 1.7 -1.8 -1.2
CNCE 2022-12-01 5626.2 1.8 -1.9 -1.2
CNCE 2022-11-30 5502.4 1.7 -1.8 -1.2
CNCE 2022-11-29 5421.4 1.7 -1.8 -1.1
CNCE 2022-11-28 5695.2 1.8 -1.9 -1.2
CNCE 2022-11-25 5797.6 1.8 -1.9 -1.3

CNCE Growth Metrics

    Its year over year price growth rate is now at -15.76%.
  • Its 4 year cash and equivalents growth rate is now at 15.34%.
  • The 5 year net income to common stockholders growth rate now stands at -51.45%.
CNCE's revenue has moved down $33,488,000 over the prior 15 months.

The table below shows CNCE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.042 -109.663 -126.806
2022-06-30 0.577 -102.341 -124.58
2022-03-31 32.573 -66.764 -95.12
2021-12-31 32.578 -55.154 -80.051
2021-09-30 32.572 -44.904 -66.322
2021-06-30 33.53 -46.553 -58.552

CNCE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CNCE has a Quality Grade of B, ranking ahead of 78.61% of graded US stocks.
  • CNCE's asset turnover comes in at 0.223 -- ranking 188th of 680 Pharmaceutical Products stocks.
  • SRNE, VBLT, and ISEE are the stocks whose asset turnover ratios are most correlated with CNCE.

The table below shows CNCE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.223 1 -0.784
2021-03-31 0.051 1 -0.738
2020-12-31 0.047 1 -0.595
2020-09-30 0.049 1 -0.584
2020-06-30 0.040 1 -0.577
2020-03-31 0.000 1 -0.647

CNCE Price Target

For more insight on analysts targets of CNCE, see our CNCE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.33 Average Broker Recommendation 1.42 (Moderate Buy)

CNCE Stock Price Chart Interactive Chart >

Price chart for CNCE

CNCE Price/Volume Stats

Current price $4.42 52-week high $7.37
Prev. close $4.52 52-week low $2.57
Day low $4.20 Volume 97,842
Day high $4.55 Avg. volume 451,356
50-day MA $5.47 Dividend yield N/A
200-day MA $4.87 Market Cap 211.89M

Concert Pharmaceuticals, Inc. (CNCE) Company Bio

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.

CNCE Latest News Stream

Event/Time News Detail
Loading, please wait...

CNCE Latest Social Stream

Loading social stream, please wait...

View Full CNCE Social Stream

Latest CNCE News From Around the Web

Below are the latest news stories about CONCERT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNCE as an investment opportunity.

H.C. Wainwright Remains a Buy on Concert Pharma (CNCE)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Concert Pharma (CNCE - Research Report), with a price target of $17.00. The company's shares closed yesterday at $4.79.Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Unity Biotechnology, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -10.2% and a 35.11% success rate on recommended stocks. Currently, the analyst consensus on Concert Pharma is a Strong Buy with an average price target of $18.00, implying a 275.78% upside from current levels.

Brian Anderson on TipRanks | November 22, 2022

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

MELBOURNE, Australia, November 21, 2022--The presentation includes new analyses on the effect of baseline severity and duration of current episode of hair loss on scalp hair regrowth.

Yahoo | November 21, 2022

Further weakness as Concert Pharmaceuticals (NASDAQ:CNCE) drops 13% this week, taking five-year losses to 77%

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

Yahoo | November 14, 2022

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LEXINGTON, Mass., November 09, 2022--Concert will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022.

Yahoo | November 9, 2022

Concert Pharma (CNCE) Gets a Buy from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Concert Pharma (CNCE - Research Report) today and set a price target of $17.00. The company's shares closed yesterday at $4.45.According to TipRanks, Fein is an analyst with an average return of -12.0% and a 30.84% success rate. Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Matinas BioPharma, and Wave Life Sciences.Currently, the analyst consensus on Concert Pharma is a Strong Buy with an average price target of $18.00, which is a 304.49% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $13.

Howard Kim on TipRanks | November 8, 2022

Read More 'CNCE' Stories Here

CNCE Price Returns

1-mo -0.67%
3-mo -33.03%
6-mo -4.95%
1-year 22.44%
3-year -39.62%
5-year -82.25%
YTD 40.32%
2021 -75.08%
2020 37.02%
2019 -26.49%
2018 -51.49%
2017 151.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.777 seconds.